Therapeutic Exploratory (Phase II)

3,481 trials 1,373 recruiting

Filter these 3,481 trials by condition, country, sponsor and more.

Open in Search →

PH2a, VH3739937 Proof-Of-Concept in TN HIV-1 Infected Adults Ended

2023-505780-37-00 HIV Infections 2023-12-21
A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended

2023-503315-15-00 Thrombolysis of symptomatic proximal vein thrombosis 2023-12-20
CBD, amitriptyline and tramadol drug-drug interaction study Ended

2023-508428-36-00 Neurological assessments 2023-12-19
Efficacy of oral lidocaine in preventing gastrointestinal disturbance in patients after abdominal surgery Ended

2022-503113-31-01 longitudinal laparotomy 2023-12-19
Ilofotase alfa for prevention of renal damage after cardiac surgery Ended

2023-505859-45-00 Risk for renal damage following open heart surgery 2023-12-19
RVU 120 (SEL120) to be tested in for treatment patients with solid tumors who have failed previous available standard therapy Ended

2024-515131-30-00 Relapsed / Refractory Metastatic or Advanced Solid Tumo 2023-12-18
Proof of concept treatment study of orally administered VH4004280 or VH4011499 in HIV-1 infected adults Ended

2023-505350-18-00 HIV Infections 2023-12-15
A Phase 2 study (NEPTUNE-17) to evaluate efficacy and safety of GSK3858279 in DPNP. Ended

2022-502313-28-00 Diabetic Peripheral Neuropathic Pain 2023-12-14
Focus Green: Fluorescence-guided resection Of Colorectal liver metastases Using SGM-101 and Indocyanine GREEN Ended

2023-504615-33-00 colorectal livermetastases 2023-12-12
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release… Ended

2023-505296-72-00 Idiopathic Pulmonary Fibrosis (IPF) 2023-12-12
A study to learn if atrasentan is safe and works in people with IgA nephropathy who are taking an SGLT2i Ended

2023-503828-13-00 Nephrology 2023-12-12
FLUOPANC II: A performance study of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody for fluorescence-guide… Ended

2023-510481-27-00 Pancreatic tumor 2023-12-11
Study of ART0380 in Advanced/Metastatic Solid Tumors Patients (ARTIST) Ended

2023-504153-12-00 Advanced or Metastatic Solid Tumors 2023-12-07
Moisturiser effect on the skin barrier in atopic dermatitis Ended

2023-508560-29-00 Atopic dermatitis 2023-12-07
Etude de dose de l’acide tranexamique dans la prothèse totale de hanche pour réduire la perte d’hémoglobine post-opératoire. Etude de phase … Ended

2022-502532-38-01 Arthropathy of Hip 2023-12-06
Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504673-20-00 Ulcerative Colitis 2023-12-06
Functional Constipation: A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Le… Ended

2022-501947-34-00 Functional Constipation (FC) 2023-12-05
BRIGHT - A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug… Ended

2022-502001-15-00 Acute Ischemic Stroke (AIS) 2023-12-05
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis Ended

2022-503005-38-00 Ulcerative Colitis 2023-12-04
A Ph2 dose-finding study (MARS-17) to evaluate the efficacy and safety of GSK3858279 in adults with knee osteoarthritis pain. Ended

2022-502799-22-00 Knee osteoarthritis pain 2023-11-29
BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidne… Ended

2023-503336-41-00 Prophylaxis of Renal Allograft Rejection 2023-11-29
ITPP as an adjunctive treatment for progressive respiratory failure in COVID-19 and other pulmonary parenchymal infections [BREATH2] Ended

2024-517878-21-00 COVID-19 and other pulmonary parenchyma infections. 2023-11-28
A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended

2022-502716-37-00 Recurrent or advanced/metastatic solid tumors who are i 2023-11-27
A study to test whether BI 765845 helps people who have had a heart attack Ended

2022-502788-39-00 acute myocardial infarction 2023-11-27